Freedom Biosciences

Executive Summary

Freedom Biosciences is a Boston-based biotechnology company developing next-generation neuropsychiatric therapeutics targeting ketamine and 5ht2a mechanisms. Founded in 2021 and co-led by a Yale psychiatrist and a venture investor, the company aims to create improved treatments for mental health and substance use disorders by enhancing the efficacy and safety profiles of rapid-acting antidepressants. Currently in Phase 3 clinical development, Freedom Biosciences focuses on combination therapies to address the limitations of existing psychedelic-based treatments. The company's platform leverages foundational discoveries in rapid-acting antidepressants, positioning it to potentially disrupt the psychiatric treatment landscape. With a strong scientific foundation and late-stage clinical pipeline, Freedom Biosciences is well-positioned to capitalize on the growing demand for innovative mental health therapies. However, it faces competition from other psychedelic and novel antidepressant developers, as well as regulatory and reimbursement hurdles. The company's progress in Phase 3 trials and ability to secure partnerships or financing will be critical to its near-term success.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Topline Data for Lead Ketamine-Based Candidate65% success
• Q4 2026FDA Breakthrough Therapy Designation for 5ht2a Program40% success
• Q2 2026Strategic Partnership or Series C Financing75% success